Compare GUT & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GUT | MYGN |
|---|---|---|
| Founded | 1999 | 1991 |
| Country | United States | United States |
| Employees | N/A | 2700 |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 540.2M | 481.6M |
| IPO Year | N/A | 1996 |
| Metric | GUT | MYGN |
|---|---|---|
| Price | $6.07 | $5.14 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $8.06 |
| AVG Volume (30 Days) | 180.9K | ★ 1.3M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 10.93% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $771,400,000.00 |
| Revenue This Year | N/A | $7.19 |
| Revenue Next Year | N/A | $5.64 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 2.33 |
| 52 Week Low | $4.71 | $3.76 |
| 52 Week High | $6.20 | $11.44 |
| Indicator | GUT | MYGN |
|---|---|---|
| Relative Strength Index (RSI) | 47.53 | 51.59 |
| Support Level | $5.79 | $4.82 |
| Resistance Level | $6.12 | $5.67 |
| Average True Range (ATR) | 0.06 | 0.39 |
| MACD | 0.00 | 0.13 |
| Stochastic Oscillator | 32.35 | 64.60 |
Gabelli Utility Trust operates as a diversified closed-end investment management company. The fund's primary objective is the long-term growth of capital and income. To achieve its objective, the fund may invest its assets in common stocks and other securities of foreign and domestic companies involved in providing products, services, or equipment for the generation or distribution of electricity, gas, & water; and telecommunications services or infrastructure operations. It invests in various sectors, of which Electric Integrated, Water, Telecommunications, and U.S. Government Obligations and others.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.